Physician profile
Lingareddy S Devireddy
NPI 1386680494
$4,422.61
in general payments reported to CMS, 2019-2025
29 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $226 · 2021: $240 · 2022: $682 · 2023: $1,184 · 2024: $790 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $864.47 | 2019-2024 | Lifevest |
| Medtronic, INC. | $637.52 | 2022-2025 | Micra, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $548.38 | 2019-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Shockwave Medical, INC | $352.45 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $327.69 | 2019 | |
| Abiomed | $216.56 | 2020-2024 | Impella |
| Impulse Dynamics (USA) INC. | $162.59 | 2023 | Optimizer |
| Amgen INC. | $160.14 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $121.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.70 | 2023-2025 | Jardiance |
| Medtronic Vascular, INC. | $112.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.76 | 2019-2024 | |
| Preventice Services, LLC | $88.05 | 2019 | |
| Lantheus Medical Imaging, INC. | $87.84 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $73.42 | 2019-2023 | Farxiga |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $71.39 | 2019-2023 | Camzyos |
| Merck Sharp & Dohme LLC | $70.01 | 2021-2025 | Verquvo |
| Pfizer INC. | $58.16 | 2019-2021 | |
| Novo Nordisk INC | $54.52 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $44.16 | 2019 | |
| Chiesi USA, INC. | $22.73 | 2023 | Cleviprex, Kengreal |
| Kiniksa Pharmaceuticals International, Plc | $22.09 | 2024 | Arcalyst |
| Astellas Pharma US INC | $20.00 | 2019 | |
| Heartflow, INC. | $18.87 | 2019 | |
| Covidien LP | $17.90 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.42 | 2021 | |
| Amarin Pharma, INC. | $15.80 | 2019 | |
| Teleflex LLC | $14.38 | 2020 | |
| Medicomp INC | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lingareddy Devireddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.